{"schema_version":"secwatch.filing_event.v1","accession":"0001827506-24-000032","form_type":"8-K","ticker":null,"cik":"0001827506","company_name":"Tourmaline Bio, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.455532+00:00","generated_at":"2026-06-02T02:39:07.089576+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tourmaline Bio Q1 2024 net loss $13.3M; cash $350.3M; Phase 2 TRANQUILITY initiated","bullets":["Net loss $13.3M ($0.55 basic/diluted loss per share) for Q1 2024, compared to $7.5M ($8.28) in Q1 2023.","Cash, cash equivalents and investments $350.3M as of March 31, 2024, providing cash runway into 2027.","Initiated Phase 2 TRANQUILITY trial in ASCVD/CKD in April 2024; topline data expected in H1 2025.","Plans to initiate pivotal Phase 3 trial for TOUR006 in TED in H2 2024; Phase 2b spiriTED topline in 2025.","Completed $172.5M follow-on offering in January 2024, net proceeds $161.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001827506-24-000032","json":"https://secwatch.observer/filing/0001827506-24-000032.json","markdown":"https://secwatch.observer/filing/0001827506-24-000032.md","text":"https://secwatch.observer/filing/0001827506-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/0001827506-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/trml-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:39:07.089576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6daeeba76c6ff25ac6df1d6121623688961bd34","claim":"Tourmaline Bio, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $13.3 million for the first quarter of 2024 and $7.5 million for the first quarter of 2023, resulting in ba.","evidence_excerpt":"On May 13, 2024, Tourmaline Bio, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/0001827506-24-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $13.3 million for the first quarter of 2024 and $7.5 million for the first quarter of 2023, resulting in ba"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}